Screening for bladder cancer: A perspective

Yair Lotan, Robert S. Svatek, Núria Malats

Producción científica: Review articlerevisión exhaustiva

43 Citas (Scopus)


Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.

Idioma originalEnglish (US)
Páginas (desde-hasta)13-18
Número de páginas6
PublicaciónWorld Journal of Urology
EstadoPublished - feb 2008
Publicado de forma externa

ASJC Scopus subject areas

  • Urology


Profundice en los temas de investigación de 'Screening for bladder cancer: A perspective'. En conjunto forman una huella única.

Citar esto